BioDiem secures Japanese patent for BDM-I
BioDiem (ASX:BDM) has expanded its IP protection, securing another Japanese patent for antimicrobial compound BDM-I.
The new patent covers BDM-I as a treatment for malaria and the STD trichomoniasis - both protozoic infections.
BioDiem has already secured similar patents in Europe and the US, and also has patents across all three markets covering BDM-I’s treatment of vulvovaginitis infections caused by thrush, gonorrhoea and chlamydia.
“This latest protozoal patent, coupled with our previous vulvovaginitis patent in key markets, means we now have a comprehensive intellectual property set for the treatment of common female genital health complaints,” BioDiem CEO Julie Phillips said.
BioDiem also has BDM-I patents in Canada, China and Singapore. The company has separately licensed hepatitis B and D vaccine technology from the University of Canberra.
The company is evaluating BDM-I against a range of additional targets, including pneumocystosis, fungal infections and tuberculosis, and the parasitic worms that cause schistosomiasis.
BioDiem shares were trading 11.11% higher at $0.03 as of around 2 pm on Thursday.
Anti-inflammatory drug may help treat alcohol use disorder
A drug that is already FDA-approved for treating inflammatory conditions may help reduce both...
Osteoarthritis study uncovers new genetic links, drug targets
The genome-wide association study (GWAS) uncovered over 900 genetic associations, more than 500...
How brain cells are affected by Tourette syndrome
US researchers have conducted a cell-by-cell analysis of brain tissue from individuals with...
